Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Mar 16;3(1):20180102.
doi: 10.1515/pp-2018-0102. eCollection 2018 Mar 1.

Therapeutic Efficacy of Systemic Therapy for Colorectal Peritoneal Carcinomatosis: Surgeon's Perspective

Affiliations
Free PMC article

Therapeutic Efficacy of Systemic Therapy for Colorectal Peritoneal Carcinomatosis: Surgeon's Perspective

Jan Franko. Pleura Peritoneum. .
Free PMC article

Abstract

Treatment choices for colorectal peritoneal carcinomatosis/metastases include systemic therapy and increasingly cytoreductive surgery with intraperitoneal chemotherapy delivery. These options are best considered as complementary and not exclusive alternatives. Two prospective randomized trials support use of peritonectomy procedures and intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis. This overview examines efficacy, limitations and landscape of systemic therapy focusing on colorectal peritoneal carcinomatosis. Observations from literature support notions that (1) systemic therapy provides survival benefit for all prototypical patients with mCRC irrespective of metastatic disease site; (2) the magnitude of this benefit is considerably reduced among patients with peritoneal metastases who consequently experience significantly shorter overall survival; (3) efficacy of systemic therapy improved over time but at a slower pace for those with carcinomatosis; (4) this therapeutic difference has not diminished with introduction of targeted therapy, but perhaps widened; (5) further research of cytoreductive surgery and/or intraperitoneal regional therapies is thus a multidisciplinary responsibility of the entire oncology community; (6) peritonectomy procedures with intraperitoneal regional therapy are not scientifically supported in absence of systemic therapies.

Keywords: cytoreduction; hyperthermia; intraperitoneal chemotherapy; intraperitoneal therapy; peritoneal surface; peritonectomy.

Conflict of interest statement

Competing interests: Not applicable.

Figures

Figure 1:
Figure 1:
Overall survival in patients with metastatic colorectal cancer with metastases in a single organ. Adapted with permission from [10].
Figure 2:
Figure 2:
Overall survival of mCRC treated by first-line systemic therapy in 14 prospective randomized trials. Individual groups are selected by peritoneal involvement (solid lines - mCRC with peritoneal involvement; dashed lines – mCRC without peritoneal involvement) and number of metastatic disease sites (1 or ≥2). Adapted with permission from [10].
Figure 3:
Figure 3:
Median overall survival in selected studies of systemic chemotherapy published after adoption of oxaliplatinum and irinotecan. All presented studies are secondary/retrospective analysis of individual patient data collected prospectively on randomized trials of systemic therapy for mCRC. Larger size of circle corresponds to larger dataset. Blue circles=mCRC patients without peritoneal involvement, red circles=patients with colorectal peritoneal carcinomatosis (pmCRC+).
Figure 4:
Figure 4:
Response rates depending on site of metastases in mCRC patients treated with historical 5-FU combinations. Data from Royal Marsden Hospital studies [7].
Figure 5:
Figure 5:
Hazard ratios for overall survival by site of metastases in cytotoxic-only therapy (left panel) and combined therapy including at least one targeted agent (right panel). * denotes statistical significance at least p<0.05. Data from [10].

Similar articles

See all similar articles

References

    1. Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, et al. Group EG-ITC, Cancer Research UK, Arbeitsgruppe Lebermetastasen und-tumoren in der Chirurgischen Arbeitsgemeinschaft O, Australasian Gastro-Intestinal Trials G, Federation Francophone de Cancerologie D. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2013;14:1208–15. - PubMed
    1. Ruers T, Van Coevorden F, Punt CJ, Pierie JE, Borel-Rinkes I, Ledermann JA, et al., European Organisation for R, Treatment of C, Gastro-Intestinal Tract Cancer G, Arbeitsgruppe Lebermetastasen und tumoren in der Chirurgischen Arbeitsgemeinschaft O, National Cancer Research Institute Colorectal Clinical Study G. Local Treatment of Unresectable Colorectal Liver Metastases: results of a Randomized Phase II Trial. J Natl Cancer Inst. 2017;109. - PMC - PubMed
    1. NCCN Guidelines: Colon Cancer. 2018. Accessed February 4, 2018, 2018. http://www.nccn.org/professionals/physician_gls/pdf/colon.pdf.)
    1. Abdalla EK, Vauthey JN, Ellis LM, Ellis V, Pollock R, Broglio KR, et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg. 2004;239: 818–25. discussion 25–7. - PMC - PubMed
    1. Adam R, Pascal G, Castaing D, Azoulay D, Delvart V, Paule B, et al. Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases?. Ann Surg. 2004;240: 1052–61. discussion 61–4. - PMC - PubMed

LinkOut - more resources

Feedback